Zealand Pharma AS (ZLDPF)
135.65
+2.24
(+1.68%)
USD |
OTCM |
Sep 20, 16:00
Zealand Pharma Enterprise Value: 8.380B for Sept. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 20, 2024 | 8.380B |
| September 19, 2024 | 8.221B |
| September 18, 2024 | 8.221B |
| September 17, 2024 | 8.313B |
| September 16, 2024 | 8.313B |
| September 13, 2024 | 8.459B |
| September 12, 2024 | 8.036B |
| September 11, 2024 | 8.120B |
| September 10, 2024 | 7.678B |
| September 09, 2024 | 7.624B |
| September 06, 2024 | 7.733B |
| September 05, 2024 | 7.559B |
| September 04, 2024 | 7.837B |
| September 03, 2024 | 7.695B |
| August 30, 2024 | 7.695B |
| August 29, 2024 | 7.695B |
| August 28, 2024 | 7.695B |
| August 27, 2024 | 7.802B |
| August 26, 2024 | 7.802B |
| August 23, 2024 | 8.030B |
| August 22, 2024 | 8.139B |
| August 21, 2024 | 8.214B |
| August 20, 2024 | 8.153B |
| August 19, 2024 | 8.304B |
| August 16, 2024 | 8.810B |
| Date | Value |
|---|---|
| August 15, 2024 | 8.473B |
| August 14, 2024 | 8.474B |
| August 13, 2024 | 8.190B |
| August 12, 2024 | 7.674B |
| August 09, 2024 | 7.999B |
| August 08, 2024 | 7.715B |
| August 07, 2024 | 7.694B |
| August 06, 2024 | 7.559B |
| August 05, 2024 | 7.167B |
| August 02, 2024 | 8.076B |
| August 01, 2024 | 8.076B |
| July 31, 2024 | 8.191B |
| July 30, 2024 | 8.143B |
| July 29, 2024 | 7.699B |
| July 26, 2024 | 7.924B |
| July 25, 2024 | 8.379B |
| July 24, 2024 | 7.977B |
| July 23, 2024 | 7.896B |
| July 22, 2024 | 7.757B |
| July 19, 2024 | 7.694B |
| July 18, 2024 | 7.615B |
| July 17, 2024 | 7.694B |
| July 16, 2024 | 8.425B |
| July 15, 2024 | 8.369B |
| July 12, 2024 | 8.332B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
412.20M
Minimum
May 11 2022
8.888B
Maximum
Jun 28 2024
2.069B
Average
1.237B
Median
Aug 25 2020
Enterprise Value Benchmarks
| Novo Nordisk AS | 566.80B |
| Eli Lilly and Co | 855.33B |
| Altimmune Inc | 388.74M |
| Genmab AS | 13.95B |
| Viking Therapeutics Inc | 6.873B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.26M |
| Revenue (Quarterly) | 4.927M |
| Total Expenses (Quarterly) | 43.56M |
| EPS Diluted (Quarterly) | -0.6741 |
| Gross Profit Margin (Quarterly) | 72.20% |
| Profit Margin (Quarterly) | -857.7% |
| Earnings Yield | -1.25% |
| Normalized Earnings Yield | -1.009 |